SK Bioscience has extended the scope of vaccine development in collaboration with the global pharmaceutical company Sanofi. The company aims to advance the pneumococcal conjugate vaccine currently being developed to the next-generation vaccine.

SK Bioscience and Sanofi announced on December 23 that they have signed an agreement to co-develop the next-generation pneumococcal conjugate vaccine for infants and young children. The new vaccine will provide a broad preventive effect compared to the currently commercialized products.

This contract extends the scope of collaboration that both companies have previously signed for the development and commercialization of 'GBP410,' a 21-valent pneu